Parhofer K G, Göke B
Medizinische Klinik II-Grosshadern, Klinikum der Ludwig-Maximilians-Universität München.
MMW Fortschr Med. 2002 May 2;144(18):34-6, 38-9.
Good glucose control is a prerequisite for the prevention of long-term complications in type 2 diabetics. In recent years, two new groups of substances have been approved for the oral treatment of type 2 diabetes: glinides and glitazones. The former are short-acting agents that promote insulin secretion and offer an alternative to the sulfonylureas, in particular in patients with irregular eating habits and high postprandial glucose peaks. The glitazones improve one of the disorders underlying type 2 diabetes, insulin resistance. They are used in particular in patients who are inadequately controlled with a sulfonylurea or metformin and who show insulin resistance. Both groups of substances are a useful addition to the antidiabetic drug armamentarium. Endpoint studies involving these substances have, however, not yet been performed.
良好的血糖控制是预防2型糖尿病患者长期并发症的前提条件。近年来,有两类新型物质已被批准用于2型糖尿病的口服治疗:格列奈类和噻唑烷二酮类。前者是促进胰岛素分泌的短效药物,可作为磺脲类药物的替代品,尤其适用于饮食习惯不规律和餐后血糖峰值高的患者。噻唑烷二酮类药物可改善2型糖尿病的潜在病症之一——胰岛素抵抗。它们特别适用于使用磺脲类药物或二甲双胍治疗效果不佳且存在胰岛素抵抗的患者。这两类物质都是抗糖尿病药物库中的有益补充。然而,尚未开展涉及这些物质的终点研究。